People with a high genetic risk for heart disease may still have normal cholesterol and blood pressure, especially when they are young and active. Routine measurements do not capture inherited risk.
Researchers at Mass General Brigham published a validation study in the Journal of the American College of Cardiology introducing an integrated polygenic risk score, a single genetic test that estimates inherited risk for eight different cardiovascular and metabolic conditions at once. It's already available to clinicians through the Mass General Brigham Laboratory for Molecular Medicine and Broad Clinical Labs.
Your cholesterol panel isn't the whole story
Cardiovascular disease is still the number one killer worldwide, responsible for roughly a third of all deaths globally. The standard playbook for catching it early has barely changed in decades: check your age, blood pressure, cholesterol, and lifestyle habits, then estimate your risk from there.
The problem is that this approach measures the symptoms of risk, not the sourceof it. Plenty of people carry a heavy genetic predisposition toward heart disease and related conditions but don't raise a single red flag during a routine physical, because they're young, active, and haven't accumulated the traditional warning signs yet. By the time cholesterol or blood pressure numbers start looking scary, the genetic risk has often been sitting there for decades.
What the test actually screens for
The researchers built their tool by pulling validated genetic risk models from the Polygenic Score Catalog, a public database of DNA-based risk scores, and combining them into one integrated report. It was trained on genetic and health data from more than 245,000 participants in the NIH's All of Us Research Program, then validated against over 53,000 people in the Mass General Brigham Biobank. This was a large validation cohort rather than a small pilot.
The single test evaluates inherited risk across:
- Coronary artery disease
- Atrial fibrillation
- Type 2 diabetes
- Venous thromboembolism
- Thoracic aortic aneurysm
- Extreme hypertension
- Severe hypercholesterolemia
- Elevated lipoprotein(a)
What the numbers show
People in the top 10% of genetic risk for coronary artery disease were 3.7 times more likely to develop it, compared to people with average genetic risk. For type 2 diabetes, the top 10% genetic risk group was 3.1 times more likely to develop the disease.
For context, co-senior author Dr. Aniruddh Patel pointed out that those effect sizes are larger than what you'd typically see from established risk factors like high blood pressure or high cholesterol, which usually carry around a two-fold increased risk. Genetic risk is present from birth, before lifestyle-related warning signs appear.
When the researchers added the polygenic score to standard risk calculators, it improved risk reclassification for borderline coronary artery disease cases by roughly 17-18%. Some patients with borderline results moved into a category that could change clinical decisions.
How this relates to family health history
Family health history offers another view of inherited risk. What happened to your parents, grandparents, aunts, and uncles. A polygenic risk score is basically a more precise, lab-verified version of the question every doctor asks at your first appointment: "Does heart disease run in your family?" A score can add genetic data to that account, but it does not replace it.
The difference is that most people can't answer that question with any real confidence. Family health details get lost, misremembered, or never discussed. Tools that help families track and share that history remain useful alongside genetic tests. A DNA report is only as useful as your ability to act on it, and that starts with knowing what to watch for and who in your family already dealt with it.
Limits of the test
This tool isn't a crystal ball, and the researchers are upfront about its limits. Most of the underlying genetic models were developed primarily using data from people of European ancestry, so accuracy may be lower for people outside that group. The researchers say broader validation is needed.
There's also no large randomized trial yet proving that acting on a polygenic risk score actually changes outcomes, meaning that fewer people go on to have heart attacks or strokes because they knew their score. That evidence is still being built. And right now, insurance coverage is inconsistent, so access may depend heavily on where you live and which health system you use.
Dr. Patel put it plainly: clinicians should treat a polygenic risk score the way they'd treat any other risk factor: one input among several, not a standalone verdict. It's a nudge toward earlier screening or more aggressive prevention, not a diagnosis.
When to ask your doctor
If heart disease, diabetes, or blood clotting disorders run in your family, or if your traditional risk numbers keep landing in that maddening "borderline" zone, this is worth a conversation with your doctor. It won't replace your annual bloodwork, and it's not going to be available or necessary for everyone. But for people with a family history that feels heavier than their lab results suggest, a test like this could finally put a number on the risk that's been circling the family for generations.
Bring a written family health history to that conversation. It will help your doctor decide whether genetic testing would add useful information to your current risk profile.
Frequently Asked Questions
A polygenic risk score combines the small effects of many different genetic variants into a single number that estimates your inherited risk for a particular condition. Unlike single-gene tests (like BRCA testing for breast cancer), it accounts for the fact that most common diseases, including heart disease and type 2 diabetes, are influenced by hundreds or thousands of genetic variants working together.